Recently we wrote about how the combination of the drugs Alimta and Paraplatin showed an improvement in the survival rates of people with mesothelioma. Another breakthrough has been released about the combination of two treatments that resulted in effective palliative care for mesothelioma patients. Researchers from Denmark have reported that the combination of Navelbine® (vinorelbine) and Platinol® (cisplatin) is highly active in patients with newly diagnosed non-resectable malignant pleural mesothelioma. Overall, the one-year survival was 61%, the two-year survival was 31%, and the three-year survival was 4%.

The study evaluated a regimen of Navelbine and Platinol for the treatment of 54 patients with non-resectable mesothelioma. The median number of cycles of chemotherapy administered was four and there were two complete responses and 14 partial responses. The median survival was 16.8 months, and the median time to tumor progression was 7.2 months.

The researchers have concluded that these results were as good or better than currently used combinations for treatment of mesothelioma. Therefore, this drug combination merits further investigation as the results appear to be superior to previous studies with Gemzar-based combinations.

For Full Article, Click Here.